Article

Prenylation of HDAg and antiviral drug development.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305-5187, USA.
Current topics in microbiology and immunology (Impact Factor: 3.47). 02/2006; 307:133-49. DOI: 10.1007/3-540-29802-9_7
Source: PubMed

ABSTRACT Hepatitis delta virus (HDV) is an important cause of acute and chronic liver disease. Current medical therapies are unable to effectively eradicate HDV infections. Research into the molecular virology of the HDV life cycle has revealed a fascinating collection of biology. These insights are now beginning to be translated into new potential treatment strategies. For example, an essential step in the virus assembly process involves the post-translational lipid modification of a specific HDV protein, namely prenylation of large delta antigen. Preventing prenylation abolishes virus particle formation. Drugs capable of specifically inhibiting prenylation have been developed for use in humans. These agents represent a new class of antiviral agents, with HDV as a first target. Here, a brief review of the HDV life cycle emphasizing the role of prenylation is presented along with implications for drug development and therapy.

0 Followers
 · 
126 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coinfection of hepatitis B virus (HBV) with HIV, hepatitis C virus (HCV) and hepatitis D virus (HDV) is common because of shared modes of transmission. Increasing prevalence of high risk sexual behavior and intra venous drug use (IVDU) contributes to a majority of the cases with coinfection. Occult HBV or prior HBV infection is frequently encountered in patients coinfected with HIV or HCV. Although HBV is a preventable disease, failure to screen and inadequate vaccination in the high risk individuals account for vast under-recognition of the cases with HBV infection. Chronic liver disease from viral hepatitis B and C has emerged as the major cause of morbidity and mortality worldwide as well as in the United States. This is especially true in cases coinfected with HIV. The potential long term risks of untreated hepatitis include cirrhosis and hepatocellular carcinoma. There have been several advancements in the understanding of natural history and management options of chronic viral hepatitis. This article discusses and reviews the natural history, epidemiology, and management of HBV patients coinfected with HIV, HCV, or HDV. It includes an updated summary of the outcomes with liver transplantation and post transplant recurrence in the coinfected population with HBV. It also discusses the role of occult HBV in HIV and HCV coinfection respectively.
    Current Hepatitis Reports 12/2011; 10(4). DOI:10.1007/s11901-011-0115-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immigration is fuelling a new reservoir of hepatitis D virus (HDV) in Europe, and hepatitis D still represents an important medical problem in the USA. The disease continues to be a major medical scourge in the developing world, in particular in countries such as Pakistan, Mongolia and Mauritania. New therapeutic strategies are being developed to disrupt interactions between HDV and its viral partner HBV, or with the host. Blocking or modifying the hepatitis B surface antigen (HBsAg) might interfere with the uptake or release of the hepatitis D virion; interference with host-mediated post-translational changes of proteins that are crucial to the HDV life cycle, such as prenylation, is another potential therapeutic option. At present, however, the only realistic option is to optimize IFN-α therapy. As eradication of HBsAg is the ultimate end point of therapy, long-term interferon administration might be required, raising an issue of tolerance in patients. Treatment with IFN-λ is a potential alternative approach to IFN-α; treatment of hepatitis C with this cytokine seems to cause fewer adverse effects than IFN-α and, therefore, might be more suitable for long-term treatment of HDV.
    Nature Reviews Gastroenterology &#38 Hepatology 09/2013; DOI:10.1038/nrgastro.2013.164 · 10.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interferon is the only therapy for chronic hepatitis D. Nucleos(t)ides are not effective against the helper hepatitis B virus. The current therapeutic recommendation is a weekly dose of pegylated interferon (PEG-IFN)-α, for 12–18 months. Serum HDV-RNA only becomes undetectable after 6 months of therapy in about a quarter of the patients. Hepatitis D virus (HDV) may relapse in patients if they remain HBsAg positive. Although the end-point of therapy is the clearance of the HBsAg, this is seldom achieved. Current management of HDV patients is based on standard practices which should be pragmatic and individualized.
    Liver international: official journal of the International Association for the Study of the Liver 02/2013; 33(s1). DOI:10.1111/liv.12058 · 4.41 Impact Factor